Homevale's founder and partners have invested in and operated businesses across the home-based care continuum, from the nation's largest providers to high-growth technology platforms.
A Homevale partner was a significant investor in LHC Group, helping drive its growth into the largest home health and hospice operator in the United States, with 960+ locations across 37 states. Acquired by UnitedHealth Group/Optum for $5.4 billion in 2023.
A Homevale partner acquired and merged this AI-powered clinical decision support platform for home health and hospice, then served as a senior executive helping scale it to serve approximately one-third of all Medicare home health and hospice recipients. The business was sold for an undisclosed sum in 2025.
A Homevale partner was an early investor in BioScrip, helping drive its growth as a national home infusion therapy provider. BioScrip later merged with Option Care in 2019 to form Option Care Health (NASDAQ: OPCH), now the largest independent home infusion services provider in the U.S.
A Homevale partner was the largest investor in an independent infusion nursing services provider delivering in-home IV therapy across multiple states as a cost-effective alternative to hospital-based infusion. Business name redacted as it is a current investment.